La cadena de opciones muestra datos clave de las opciones de acciones de 180 Life Sciences a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para 180 Life Sciences..

180 Life Sciences (NASDAQ:ATNF) Bolsa, Cadena de Opciones

180 Life Sciences

180 Life Sciences Corp was formed as a clinical-stage biotechnology company, focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation, and fibrosis by employing research, and, where appropriate, combination therapy. In addition, it has acquired certain source code and intellectual property relating to the back-end technology platform to operate an online blockchain casino, and moving forward, it plans to focus the majority of its operations on the creation of the online blockchain casino, while looking to monetize certain prior development-stage therapeutic product candidates for unmet medical needs. It has one reportable operating segment, iGaming.

180 Life Sciences Corp

NIVF

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

PTIXW

PBMWW

NIVFW

PTIX

SLGL

Kirby (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEX#NYSE">KEX</a>) has outperformed the market over the past 5 years by 2.3% on an annualized basis producing an average annual return of 16.94%. Currently, Kirby has a market capitalization of $5.94 billion. 
Buying $1000 In KEX: If an investor had bought $1000 of KEX stock 5 years ago, it would be worth $2,095.47 today based on a price of $104.48 for KEX at the time of writing.
<h3>Kirby's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746229512_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Agnico Eagle Mines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEM#NYSE">AEM</a>) has outperformed the market over the past 10 years by 2.98% on an annualized basis producing an average annual return of 13.47%. Currently, Agnico Eagle Mines has a market capitalization of $55.88 billion. 
Buying $100 In AEM: If an investor had bought $100 of AEM stock 10 years ago, it would be worth $362.54 today based on a price of $111.15 for AEM at the time of writing.
<h3>Agnico Eagle Mines's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746227716_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

UBS analyst Andrew Spinola maintains Viavi Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIAV#NASDAQ">VIAV</a>) with a Neutral and lowers the price target from $11.5 to $11.

Price Target

Analyst Ratings

VIAV

UBS Maintains Neutral on Viavi Solutions, Lowers Price Target to $11

UBS analyst Taylor McGinnis maintains Twilio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) with a Buy and lowers the price target from $175 to $150.

TWLO

UBS Maintains Buy on Twilio, Lowers Price Target to $150

UBS analyst Karl Keirstead maintains Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) with a Neutral and lowers the price target from $230 to $215.

TEAM

UBS Maintains Neutral on Atlassian, Lowers Price Target to $215

UBS analyst A.J. Rice maintains Service Corp Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCI#NYSE">SCI</a>) with a Buy and lowers the price target from $90 to $88.

UBS Maintains Buy on Service Corp Intl, Lowers Price Target to $88

UBS analyst Seth Gilbert maintains Open Text (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTEX#NASDAQ">OTEX</a>) with a Neutral and lowers the price target from $32 to $28.

OTEX

UBS Maintains Neutral on Open Text, Lowers Price Target to $28

Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) has outperformed the market over the past 20 years by 6.5% on an annualized basis producing an average annual return of 14.72%. Currently, Marsh &amp; McLennan Cos has a market capitalization of $111.99 billion. 
Buying $1000 In MMC: If an investor had bought $1000 of MMC stock 20 years ago, it would be worth $15,188.11 today based on a price of $227.29 for MMC at the time of writing.
<h3>Marsh &amp; McLennan Cos's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746226815_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Marsh & McLennan Cos 20 Years Ago Would Be Worth This Much Today

UBS analyst Peter Grom maintains Utz Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTZ#NYSE">UTZ</a>) with a Neutral and lowers the price target from $15 to $13.5.

UBS Maintains Neutral on Utz Brands, Lowers Price Target to $13.5

UBS analyst Peter Grom maintains Hershey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) with a Neutral and lowers the price target from $175 to $170.

UBS Maintains Neutral on Hershey, Lowers Price Target to $170

UBS analyst Joseph Spak maintains General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) with a Neutral and lowers the price target from $51 to $50.

UBS Maintains Neutral on General Motors, Lowers Price Target to $50

UBS analyst Taylor McGinnis maintains Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) with a Buy and lowers the price target from $22 to $19.

FRSH

UBS Maintains Buy on Freshworks, Lowers Price Target to $19

Press Releases

180 Life Sciences Corp. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Rule and Expands into the Global iGaming Sector

180 Life Sciences Corp. Interim CEO, Blair Jordan, Issues Letter to Stockholders; Provides Update on Newly Acquired Gaming Technology Platform

Elray Resources Announces Strategic Sale of Crypto iGaming Technology

Management

180 Life Sciences Corp. Appoints Mr. Jay Goodman to Board of Directors

180 Life Sciences Corp. Retains Senior Technology Consultant and Commences Gaming Technology Platform Integration

180 Life Sciences Corp. Announces the Appointment of Stephen Shoemaker to Board of Directors

180 Life Sciences Corp. Regains Full Compliance with Nasdaq Continued Listing Rules

Offerings

180 Life Sciences Corp. Announces Pricing of $2.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under NASDAQ Rules

Comments

180 Life Sciences

180 Life Sciences (ATNF) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL